XNASADAG
Market cap67mUSD
Dec 24, Last price
1.92USD
1D
2.13%
1Q
-12.73%
IPO
-92.67%
Name
Adagene Inc
Chart & Performance
P/E
—
P/S
4.69
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
4.94%
Rev. gr., 5y
64.33%
Revenues
18m
+94.90%
Net income
-19m
L-76.31%
CFO
-28m
L-41.47%
Earnings
Mar 27, 2025
Profile
Adagene Inc., a clinical stage biopharmaceutical company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti-CD137 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors. It also offers ADG104, an anti-PD-L1 mAb that is in Phase 2 clinical development; ADG125, a novel anti-CSF-1R mAb, which is in Phase I clinical trial; ADG206, a masked, Fc engineered anti-CD137 agonistic POWERbody, which is in preclinical; ADG153, a masked anti-CD47 IgG1 SAFEbody, which is in preclinical stage for the treatment hematologic and solid tumors; ADG138, novel HER2xCD3 POWERbody, which is in preclinical for the treatment HER2-expressing solid tumors; and ADG152, a CD20xCD3 POWERbody, which is in preclinical stage for the treatment off-tumor toxicities. The company was incorporated in 2011 and is headquartered in Suzhou, China.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | |
| Income | ||||||
Revenues | 18,111 94.90% | 9,293 -8.67% | 10,175 2,019.85% | |||
Cost of revenue | 45,312 | 93,213 | 82,539 | |||
Unusual Expense (Income) | ||||||
NOPBT | (27,200) | (83,921) | (72,364) | |||
NOPBT Margin | ||||||
Operating Taxes | 1,691 | 459 | 1,702 | |||
Tax Rate | ||||||
NOPAT | (28,892) | (84,380) | (74,066) | |||
Net income | (18,946) -76.31% | (79,972) 9.28% | (73,178) 345.24% | |||
Dividends | ||||||
Dividend yield | ||||||
Proceeds from repurchase of equity | (3,654) | 147,432 | ||||
BB yield | 7.96% | -57.07% | ||||
| Debt | ||||||
Debt current | 8,593 | 13,771 | 4,498 | |||
Long-term debt | 14,083 | 14,406 | 2,992 | |||
Deferred revenue | ||||||
Other long-term liabilities | 29 | 94 | ||||
Net debt | (87,258) | (115,582) | (166,902) | |||
| Cash flow | ||||||
Cash from operating activities | (28,455) | (48,612) | (43,415) | |||
CAPEX | (85) | (691) | (2,510) | |||
Cash from investing activities | (77) | (686) | (2,510) | |||
Cash from financing activities | (5,367) | 17,823 | 145,357 | |||
FCF | (28,117) | (83,867) | (75,486) | |||
| Balance | ||||||
Cash | 109,934 | 143,759 | 174,391 | |||
Long term investments | ||||||
Excess cash | 109,029 | 143,294 | 173,882 | |||
Stockholders' equity | (279,546) | (259,649) | (178,922) | |||
Invested Capital | 372,412 | 370,390 | 341,406 | |||
ROIC | ||||||
ROCE | ||||||
| EV | ||||||
Common stock shares outstanding | 43,790 | 43,308 | 40,026 | |||
Price | 1.55 45.77% | 1.06 -83.58% | 6.45 | |||
Market cap | 67,661 47.39% | 45,907 -82.23% | 258,354 | |||
EV | (19,597) | (69,675) | 91,452 | |||
EBITDA | (25,992) | (82,471) | (71,239) | |||
EV/EBITDA | 0.75 | 0.84 | ||||
Interest | 1,108 | 693 | 364 | |||
Interest/NOPBT | ||||||